NCT05459701View on ClinicalTrials.gov

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Nonalcoholic Fatty Liver DiseaseType 2 Diabetes
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg once daily for 24 weeks.

OTHER

Placebo

Placebo

Trial Locations (1)

31527

Rehab Hussein Werida, Damanhūr

All Listed Sponsors
collaborator

University of Alexandria

OTHER

lead

Rehab Werida

OTHER